MCMedicalCodingSoftware
Free trial
XW043S5

XW043S5 — Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5

Billable / specific codeICD-10-PCS

CMS abbreviated title: Introduce Iobenguane I-131 in Central Vein, Perc, New Tech 5

How XW043S5 is built

Every ICD-10-PCS code is seven independent character positions. Each one is a separate decision, and the meaning of a character depends on the positions before it.

  1. XSectionNew Technology — What family of procedure this is
  2. WBody systemWhich system it acts on
  3. 0Root operationThe objective — the verb of the procedure
  4. 4Body partThe specific site
  5. 3ApproachHow the site was reached
  6. SDeviceWhat was left in place, if anything
  7. 5QualifierA further distinction where one applies

Codes near XW043S5

In CMS’s own ordering, which groups codes that differ by only the last character or two — usually the approach, device or qualifier.

  • XW043NAIntroduction of Tarlatamab-dlle Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 10
  • XW043P9Introduction of Glofitamab Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 9
  • XW043PBIntroduction of Aztreonam-avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11
  • XW043Q5Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
  • XW043Q9Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9
  • XW043QBIntroduction of Iloprost into Central Vein, Percutaneous Approach, New Technology Group 11
  • XW043R9Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9
  • XW043RBIntroduction of Letetresgene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 11
  • XW043S5Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5
  • XW043W5Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5
  • XW043WBIntroduction of Fosfomycin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11
  • XW053T9Introduction of Melphalan Hydrochloride Antineoplastic into Peripheral Artery, Percutaneous Approach, New Technology Group 9
  • XW0DX38Introduction of Maribavir Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 8
  • XW0DX82Introduction of Uridine Triacetate into Mouth and Pharynx, External Approach, New Technology Group 2
  • XW0DXF5Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5
  • XW0DXJ9Introduction of Quizartinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 9
  • XW0DXK8Introduction of Sabizabulin into Mouth and Pharynx, External Approach, New Technology Group 8
ICD-10-PCSFY2026